申请人:Quest Diagnostic Investments Incorporated
公开号:US20040038294A1
公开(公告)日:2004-02-26
In accordance with the present invention, it has been discovered that introduction of hydrophilic sulfoalkyl substituents and/or hydrophilic linkers derived from homocysteic acid, cysteic acid, glycine peptides, tetraethylene oxide, and the like, offset the hydrophobicity of the acridinium ring system to produce a more soluble label which can be attached to an antibody at higher loading before precipitation and aggregation problems are encountered. Additional compounds described herein contain linkers derived from short peptides and tetraethylene oxide which increase aqueous solubility due to hydrogen bonding with water molecules. The present invention also embraces reagents for multiple acridinium labeling for signal amplification composed of a peptide bearing several acridinium esters with sulfonate groups at regularly spaced intervals for increased solubility. The invention also embraces assays employing the above-described compounds.
根据本发明,人们发现引入亲水性磺烷基取代基和/或亲水性连接体(来源于高半胱氨酸、半胱氨酸、甘氨酸肽、四亚甲基环氧乙烷等),可以抵消吖啶环系统的疏水性,从而产生一种可溶性更强的标签,在遇到沉淀和聚集问题之前,这种标签可以更高的负载量连接到抗体上。本发明中描述的其他化合物含有源自短肽和四氧化乙烯的连接体,由于与水分子的氢键作用,这些连接体增加了水溶性。本发明还包括用于信号放大的多重吖啶鎓标记试剂,该试剂由含有多个吖啶鎓酯的肽组成,肽与磺酸基之间有规律的间隔,以增加溶解度。本发明还包括采用上述化合物的检测方法。